UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 2, 2014
|
PHARMACYCLICS, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
||
|
Delaware
|
000-26658
|
94-3148201
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
995 E. Arques Avenue, Sunnyvale, California
|
94085-4521
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (408) 774-0330
|
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On April 2, 2014, Pharmacyclics, Inc. (the “Company”) granted options to purchase shares of common stock to certain its officers in the following amounts, including: (i) 40,000 to Mahkam Zanganeh, its Chief Operating Officer, (ii) 40,000 to Manmeet Soni, its Chief Financial Officer and Treasurer, and (iii) 30,000 to Heow Tan, its Chief of Quality and Technical Operations. All such options vest 25% on each of April 2, 2015, April 2, 2016, April 2, 2017 and April 2, 2018 and are subject to satisfaction of certain performance criteria with respect to each vesting period. Such performance criteria are to be determined and approved by the Compensation Committee of the Company’s Board of Directors.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
April 8, 2014
|
PHARMACYCLICS, INC.
|
|||
|
By:
|
/s/ Manmeet Soni | ||
|
Name:
|
Manmeet Soni
|
||
|
Title:
|
Chief Financial Officer
|
||